mTOR Inhibitors: Do They Help Preserve Renal Function?

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2135-2137

  Moro, J ^a,b   Almenar, L ^a   Martinez Dolz L ^a   Aguero J ^a   Rueda, J ^a   Arnau, M A ^a   Izquierdo, M ^a   Cano, O ^a   Sanchez Lazaro I ^a   Salvador, A ^a  

^a Cardiology Service   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PRESERVATION; MALE; PRIORITY JOURNAL;

ADULT; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROTEIN KINASES; SIROLIMUS; TIME FACTORS;

EID: 34548686826     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.066     Document Type: Article

References (18)

1. Gómez M., Segovia J., and Alonso-Pulpón L. Asistencia mecánica circulatoria y trasplante cardiaco. Indicaciones y situación en España. Rev Esp Cardiol 6 suppl (2006) 82F
2. Almenar L. Registro Español de Trasplante Cardiaco. XVI Informe Oficial de la Sección de Insuficiencia Cardiaca, Trasplante Cardiaco y Otras Alternativas Terapéuticas de la Sociedad Española de Cardiología. Rev Esp Cardiol 58 suppl (2005) 1310
3. Lidenfeld J., Miller G.G., Shakar S.F., et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 10 (2004) 3858
4. Eisen H.J., Tuzcu E.M., Dorent R., et al., RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349 (2003) 847
5. Vitko S., Margreiter R., Weimar, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 (2004) 1532
6. Lorber M.I., Mulgaonkar S., Butt K.M., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 (2005) 244
7. Nashan B., Curtis J., Ponticelli C., et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open- label study. Transplantation 78 (2004) 1332
8. Pascual J., Cambi V., Dissegna D., et al. Efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral© in de novo kidney transplant recipients: 24 months analysis (abstract 1010). Am J Transplant 11 5 suppl (2005) 1414
9. © exposure: 12-month results (abstract 507). Am J Transplant 8 4 suppl (2004) 297
10. © exposure: 12-month results (abstract 507). Am J Transplant 11 5 suppl (2005) 414
11. Johnson R.W.G., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777
12. Kreis H., Oberbauer R., Campistol J.M., et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15 (2004) 809
13. Mota A., Arias M., Taskinen E.I., et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4 (2004) 953
14. Mulay A.V., Hussain N., Fergusson D., et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 5 (2005) 1748
15. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517
16. Clinical Trials Insight: Everolimus in transplant rejection: ongoing trials. Available at: http://bi.adisin-sight.com/cti. Accessed February 27, 2006
17. Bocchi E., Ahualli L., Amuchasteghi M., et al. Recommendations for use of Everolimus after heart transplantation: results from a Latin-American consensus meeting. Transplant Proc 38 (2006) 937
18. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869